Interindividual variability of coumarin 7-hydroxylation in a Turkish population
- PMID: 7875181
- DOI: 10.1007/BF00191161
Interindividual variability of coumarin 7-hydroxylation in a Turkish population
Abstract
One hundred healthy Turkish volunteers (70 male, 30 female) aged from 19 to 56 years were given 5 mg coumarin p.o. after an overnight fast. Urine samples were collected before and 2, 4 and 8 h after drug administration. The extent and rate of formation of 7-OH-coumarin (7OHC) was determined by the urinary excretion of the metabolite as measured with the fluorometric method. On average, 80% of 7OHC formed was excreted in 2 h. The total amount of 7OHC formed was 59.8% (21.5%) (mean and SD, n = 100, range 17-100%) of the given dose. The percentage of 7OHC excreted during the first 2 h compared with the 7OHC excretion at 8 h was a constant and stable individual characteristic for the rate of the formation of 7OHC ('2 h coumarin test'). Although four individuals had relatively slow coumarin test values (34-40%), no clear-cut polymorphism in the rate of 7OHC formation was found. However, 7OHC formation was lower in males and in cigarette smokers.
Similar articles
-
Interindividual variability of coumarin 7-hydroxylation in healthy volunteers.Pharmacogenetics. 1992 Oct;2(5):227-33. doi: 10.1097/00008571-199210000-00005. Pharmacogenetics. 1992. PMID: 1306122
-
Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian Population.Iran J Basic Med Sci. 2013 Apr;16(4):610-4. Iran J Basic Med Sci. 2013. PMID: 24250937 Free PMC article.
-
Determination of coumarin metabolism in Turkish population.Hum Exp Toxicol. 2001 Apr;20(4):179-84. doi: 10.1191/096032701678766804. Hum Exp Toxicol. 2001. PMID: 11393269
-
Hepatitis A impairs the function of human hepatic CYP2A6 in vivo.Toxicology. 1997 Dec 5;123(3):177-84. doi: 10.1016/s0300-483x(97)00119-4. Toxicology. 1997. PMID: 9355936
-
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?Pharmacogenomics. 2007 Feb;8(2):151-8. doi: 10.2217/14622416.8.2.151. Pharmacogenomics. 2007. PMID: 17286538 Review.
Cited by
-
[Preoperative abstinence from smoking. An outdated dogma in anaesthesia?].Anaesthesist. 2005 Jun;54(6):550-9. doi: 10.1007/s00101-005-0851-0. Anaesthesist. 2005. PMID: 15895200 Review. German.
-
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.Clin Pharmacokinet. 2018 Jun;57(6):749-768. doi: 10.1007/s40262-017-0594-5. Clin Pharmacokinet. 2018. PMID: 28924743
-
Artemisinin and CYP2A6 activity in healthy subjects.Eur J Clin Pharmacol. 2008 Mar;64(3):283-92. doi: 10.1007/s00228-007-0406-1. Epub 2007 Dec 7. Eur J Clin Pharmacol. 2008. PMID: 18064444 Clinical Trial.
-
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.Antimicrob Agents Chemother. 2002 Apr;46(4):1026-31. doi: 10.1128/AAC.46.4.1026-1031.2002. Antimicrob Agents Chemother. 2002. PMID: 11897585 Free PMC article. Clinical Trial.
-
Genetics of tobacco use.Tob Induc Dis. 2004 Jun 15;2(2):81-102. doi: 10.1186/1617-9625-2-2-81. Tob Induc Dis. 2004. PMID: 19570274 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources